Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Rheumatology
Erschienen in: Clinical Rheumatology 3/2017

04.07.2016 | Original Article

Voriconazole-induced periostitis: a new rheumatic disorder

verfasst von: Marwan H. Adwan

Erschienen in: Clinical Rheumatology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Over the past few years, several reports of periostitis affecting patients treated with voriconazole appeared in the literature. As rheumatologists are likely to be called to see such patients, a review of the reported cases was undertaken. A systematic search of Pubmed and Google scholar for case reports, case series and observational studies was undertaken. Twenty-six articles including 23 case reports/case series (total 40 patients), a prospective study and two retrospective studies of 58 cases were included. Age ranged from 3 months to 77 years. Eleven cases (27.5 %) were male and 29 cases (72.5 %) were female. The duration of treatment varied from 6 weeks to 8 years (mean 53.6, SD 77.4 weeks). Most cases presented with diffuse skeletal pain affecting various sites in association with elevated alkaline phosphatase. Periostitis is increasingly reported and should be considered in patients taking voriconazole who present with bone pain and/or alkaline phosphatase elevation.
Literatur
1.
Saravolatz LD, Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36(5):630–637CrossRef
2.
Barry AL, Brown SD (1996) In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 40(8):1948–1949PubMedPubMedCentral
3.
Dickinson RP et al (1996) Novel antifungal 2-aryl-1-(1H-1, 2, 4-triazol-1-yl) butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorg Med Chem Lett 6(16):2031–2036CrossRef
4.
Radford SA, Johnson EM, Warnock DW (1997) In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41(4):841–843PubMedPubMedCentral
5.
Martin M, Yates J, Hitchcock C (1997) Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 41(1):13–16PubMedPubMedCentral
6.
Wingard JR et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116(24):5111–5118CrossRefPubMedPubMedCentral
7.
Mehrad B et al (2001) Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest J 119(1):169–175CrossRef
8.
Patterson TF et al (2000) Invasive aspergillosis disease spectrum, treatment practices, and outcomes. Medicine 79(4):250–260CrossRefPubMed
9.
Walsh TJ et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360CrossRefPubMed
10.
Wang TF et al (2009) Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant 9(12):2845–2850CrossRefPubMed
11.
Ayub A, Kenney CV, McKiernan FE (2011) Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J Clin Rheumatol 17(2):73–75CrossRefPubMed
12.
Baird JH et al (2015) Voriconazole‐induced periostitis after allogeneic stem cell transplantation. Am J Hematol 90(6):574–575CrossRefPubMed
13.
Becce F et al (2012) Clinical images: voriconazole-induced periostitis deformans. Arthritis Rheum 64(10):3490CrossRefPubMed
14.
Davis DL (2015) Voriconazole-related periostitis presenting on magnetic resonance imaging. Clin Cases Miner Bone Metab 12(1):78–81PubMedPubMedCentral
15.
Gladue HS, Fox DA (2013) Voriconazole-induced periostitis causing arthralgias mimicking a flare of granulomatosis with polyangiitis. J Clin Rheumatol 19(8):444–445CrossRefPubMed
16.
17.
18.
Lustenberger DP, Granata JD, Scharschmidt TJ (2011) Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. Orthopedics 34(11):e793–e796PubMed
19.
Paudyal S et al (2015) Fluffy periostitis induced by voriconazole. Arthritis Rheumatol 67:3297CrossRefPubMed
20.
Rad B et al (2015) Fluorosis and periostitis deformans as complications of prolonged voriconazole treatment. Ann Clin Biochem 52(Pt 5):611–614CrossRefPubMed
21.
Raghavan M, Hayes A (2014) Voriconazole-associated soft tissue ossification: an undescribed cause of glenohumeral joint capsulitis. Skeletal Radiol 43(9):1301–1305CrossRefPubMed
22.
Rossier C et al (2012) Voriconazole-induced periostitis. Eur J Nucl Med Mol Imaging 39(2):375–376CrossRefPubMed
23.
Skaug M, Spak C, Oza U (2014) Painful periostitis in the setting of chronic voriconazole therapy. Proc (Bayl Univ Med Cent) 27(4):350–352
24.
Tailor TD, Richardson ML (2015) Case 215: voriconazole-induced periostitis. Radiology 274(3):930–935CrossRefPubMed
25.
Tarlock K et al (2015) Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. Pediatr Blood Cancer 62(5):918–920CrossRefPubMed
26.
Tedja R et al (2013) Multifocal periostitis as a complication of chronic use of voriconazole in a lung transplant recipient. Transpl Infect Dis 15(4):424–429CrossRefPubMed
27.
Wise SM, Wilson MA (2011) A case of periostitis secondary to voriconazole therapy in a heart transplant recipient. Clin Nucl Med 36(3):242–244CrossRefPubMed
28.
Brown A et al (2014) Voriconazole induced periostitis: “rheumatoid arthritis” in a lung transplant patient. Am J Respir Crit Care Med 189:A1588CrossRef
29.
30.
Bucknor MD, Gross AJ, Link TM (2013) Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep 7(8):10–17PubMedPubMedCentral
31.
Chen L, Mulligan ME (2011) Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol 40(2):143–148CrossRefPubMed
32.
Gerber B et al (2012) Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 120(12):2390–2394CrossRefPubMed
33.
Rheinboldt M, Delproposto Z, Agarwal R (2015) Voriconazole-induced periostitis post transplant: an illustrative review of thoracic computed tomography imaging manifestations. Transpl Infect Dis 17:859CrossRefPubMed
34.
Wermers RA et al (2011) Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 52(5):604–611CrossRefPubMed
35.
Moon WJ et al (2014) Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis 59(9):1237–1245CrossRefPubMedPubMedCentral
36.
Skiles JL et al (2011) Fluorosis because of prolonged voriconazole therapy in a teenager with acute myelogenous leukemia. J Clin Oncol 29(32):e779–e782CrossRefPubMed
37.
Ally R et al (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33(9):1447–1454CrossRefPubMed
38.
Walsh TJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225–234CrossRefPubMed
39.
Soriano M, Manchon F (1966) Radiological aspects of a new type of bone fluorosis, periostitis deformans 1. Radiology 87(6):1089–1094CrossRefPubMed
40.
Thompson GR et al (2012) Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 56(1):563–564CrossRefPubMedPubMedCentral
41.
Pan L et al (2014) Fluoride promotes osteoblastic differentiation through canonical Wnt/β-catenin signaling pathway. Toxicol Lett 225(1):34–42CrossRefPubMed
42.
43.
Gaur T et al (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280(39):33132–33140CrossRefPubMed
44.
45.
Allen KC et al (2015) Voriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanism. Antimicrob Agents Chemother 59(12):7205–7213CrossRefPubMedPubMedCentral
46.
Silveira L et al (2000) Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 18(1):57–62PubMed
47.
Silveri F et al (1996) Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 15(5):435–439CrossRefPubMed
48.
49.
Saito A et al (2011) Endoplasmic reticulum stress response mediated by the PERK-eIF2α-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 286(6):4809–4818CrossRefPubMed
50.
Schumacher H Jr (1991) Hypertrophic osteoarthropathy: rheumatologic manifestations. Clin Exp Rheumatol 10:35–40
Metadaten
Titel
Voriconazole-induced periostitis: a new rheumatic disorder
verfasst von
Marwan H. Adwan
Publikationsdatum
04.07.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 3/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3341-7

Weitere Artikel der Ausgabe 3/2017

Clinical Rheumatology 3/2017 Zur Ausgabe

Erratum

Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism

Brief Report

Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option

Original Article

Autologous whole blood versus corticosteroid local injection in treatment of plantar fasciitis: A randomized, controlled multicenter clinical trial

Original Article

Comorbidity of gout and rheumatoid arthritis in a large population database

Original Article

Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study

Brief Report

Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise